(Q33406591)

English

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates (English)

1 reference

Europe PubMed Central

26 July 2017

phase I clinical trial

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

R K Kelley

1

1 reference

Europe PubMed Central

26 July 2017

H S Nimeiri

2

1 reference

Europe PubMed Central

26 July 2017

P N Munster

3

1 reference

Europe PubMed Central

26 July 2017

M T Vergo

4

1 reference

Europe PubMed Central

26 July 2017

Y Huang

5

1 reference

Europe PubMed Central

26 July 2017

C-M Li

6

1 reference

Europe PubMed Central

26 July 2017

J Hwang

7

1 reference

Europe PubMed Central

26 July 2017

M F Mulcahy

8

1 reference

Europe PubMed Central

26 July 2017

B M Yeh

9

1 reference

Europe PubMed Central

26 July 2017

P Kuhn

10

1 reference

Europe PubMed Central

26 July 2017

M S Luttgen

11

1 reference

Europe PubMed Central

26 July 2017

J A Grabowsky

12

1 reference

Europe PubMed Central

26 July 2017

L Stucky-Marshall

13

1 reference

Europe PubMed Central

26 July 2017

W M Korn

14

1 reference

Europe PubMed Central

26 July 2017

A H Ko

15

1 reference

Europe PubMed Central

26 July 2017

E K Bergsland

16

1 reference

Europe PubMed Central

26 July 2017

A B Benson

17

1 reference

Europe PubMed Central

26 July 2017

A P Venook

18

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 March 2013

1 reference

Europe PubMed Central

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

26 July 2017

24

1 reference

Europe PubMed Central

26 July 2017

1900-1907

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Management of hepatocellular carcinoma: An update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Pivotal role of mTOR signaling in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519998

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519998

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDT109

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406591&oldid=1749478216"